Abstract
The anti-obesity effect of the serotonin and noradrenaline reuptake inhibitor sibutramine has been attributed to a dual mechanism involving a reduction of food intake and an increase in energy expenditure. This dual action increases the possibilities for induction of a negative energy balance, the principal goal of an anti-obesity treatment. To elucidate the mechanism behind sibutramine-induced increase in energy expenditure, we applied indirect calorimetry combined with monitoring locomotor activity and body temperature. We confirm that sibutramine has both anorectic and thermogenic effects. In addition, we show here that sibutramine also causes a dose-dependent increase in locomotor activity (LMA) of rats, occurring in parallel with increase in energy expenditure. The dose of sibutramine necessary to induce an effect on locomotion and energy expenditure was only marginally higher than the dose sufficient to induce a significant reduction of food intake. The relation between LMA and energy expenditure was similar to that found with d-amphetamine, which causes both hyper-locomotion and increased energy expenditure, but was different from 2,4-dinitrophenol which causes increase in energy expenditure but not in locomotion. The ef...Continue Reading
Citations
Dec 9, 2010·Psychopharmacology·Suzanne HiggsNicholas M Barnes
May 19, 2010·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A SjödinA Astrup
Mar 5, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Anne Marie D AxelHenrik H Hansen
Aug 10, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sonja K Billes, Michael A Cowley
May 14, 2014·European Journal of Pharmacology·Yu-Wen LiNicholas J Lodge
May 10, 2007·Canadian Journal of Physiology and Pharmacology·Silvana Soriano FrassettoAnapaula Sommer Vinagre
Nov 26, 2008·The Journal of Physiology·Alastair S Garfield, Lora K Heisler
Jun 20, 2012·Neuropharmacology·Steven P Vickers, Peter G Clifton
May 19, 2010·Pharmacology, Biochemistry, and Behavior·Mitchell F RoitmanHenry R Wolfe
Apr 14, 2010·European Journal of Pharmacology·Henrik H HansenJens D Mikkelsen
Dec 23, 2009·Pharmacology, Biochemistry, and Behavior·A J TallettR J Rodgers
Dec 1, 2009·Pharmacology, Biochemistry, and Behavior·Valentina GigliucciAndrew Harkin
Dec 9, 2008·Behavioural Brain Research·A J TallettR J Rodgers
Jan 1, 2007·Obesity Research & Clinical Practice·Yuko Okamatsu-OguraMasayuki Saito
Apr 9, 2011·Obesity·Sanna K JanhunenRoger A H Adan
Jul 2, 2015·Journal of Bioenergetics and Biomembranes·A I da SilvaC J Lagranha
Nov 5, 2014·Psychopharmacology·J RouineAndrew Harkin
Dec 6, 2011·Journal of Neuroscience Methods·Christine T O NguyenMagnus Ivarsson
Jul 14, 2010·Arquivos brasileiros de endocrinologia e metabologia·Silvana S FrassettoPatrícia Pereira
Feb 1, 2007·The Journal of Clinical Endocrinology and Metabolism·Edgar G A H Van MilWim H M Saris
Sep 3, 2010·American Journal of Physiology. Endocrinology and Metabolism·Joseph M MetzgerMarc L Reitman
Jan 21, 2020·Journal of Neuroendocrinology·Tássia Karin Ferreira BorbaRaul Manhães-de-Castro
Sep 6, 2019·Journal of Traditional and Complementary Medicine·Sarayu A PaiArchana R Juvekar